SUCCESS AND FAILURE OF STRAIGHTFORWARD VERSUS SOPHISTICATED MANAGED ENTRY AGREEMENTS

被引：1
|
作者：
Van de Vijver, I [1 ]
Quanten, A. [1 ]
Knappenberg, V [1 ]
De Ridder, R. [1 ]
机构：
[1] NIHDI, Brussels, Belgium
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.885
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP336
引用
收藏
页码：A499 / A499
页数：1
相关论文
共 50 条
  • [41] THE USE OF MANAGED ENTRY AGREEMENTS (MEAS) FOR ACCESSING INNOVATIVE HEALTH TECHNOLOGIES
    Kodjamanova, P.
    Bennetts, L.
    Bellaoui, Y.
    Ciritel, A.
    Bagnall, R.
    Atanasov, P.
    VALUE IN HEALTH, 2023, 26 (12) : S290 - S290
  • [42] Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
    Ciulla, Michele
    Marinelli, Lisa
    Di Biase, Giuseppe
    Cacciatore, Ivana
    Santoleri, Fiorenzo
    Costantini, Alberto
    Dimmito, Marilisa Pia
    Di Stefano, Antonio
    HEALTHCARE, 2023, 11 (03)
  • [43] The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
    Alessandra Ferrario
    Diāna Arāja
    Tomasz Bochenek
    Tarik Čatić
    Dávid Dankó
    Maria Dimitrova
    Jurij Fürst
    Ieva Greičiūtė-Kuprijanov
    Iris Hoxha
    Arianit Jakupi
    Erki Laidmäe
    Olga Löblová
    Ileana Mardare
    Vanda Markovic-Pekovic
    Dmitry Meshkov
    Tanja Novakovic
    Guenka Petrova
    Maciej Pomorski
    Dominik Tomek
    Luka Voncina
    Alan Haycox
    Panos Kanavos
    Patricia Vella Bonanno
    Brian Godman
    PharmacoEconomics, 2017, 35 : 1271 - 1285
  • [44] Managed Entry Agreements: Learnings for Design and Implementation in Light of International Experiences
    Paredes Fernandez, Daniela Maria
    Lenz Alcayaga, Rony Christian
    VALUE IN HEALTH REGIONAL ISSUES, 2019, 20 : 51 - 59
  • [45] Stakeholder views of managed entry agreements: A literature review of national studies
    Thanimalai, Subramaniam
    Choon, Wai Yee
    Lee, Kenneth Kwing-Chin
    HEALTH POLICY OPEN, 2021, 2
  • [46] ARE TRADITIONAL MANAGED ENTRY AGREEMENTS SUITABLE FOR POTENTIALLY, CURATIVE GENE/CELL THERAPIES?
    Colasante, W.
    VALUE IN HEALTH, 2018, 21 : S192 - S192
  • [47] How can managed entry agreements contribute to coverage decisions in Latin America?
    Marti, Sebastian Garcia
    Pichon-Riviere, Andres
    Augustovski, Federico
    Espinoza, Manuel
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2024, 40 (01)
  • [48] Managing Risk and Uncertainty in Health Technology Introduction: The Role of Managed Entry Agreements
    Kanavos, Panos
    Ferrario, Alessandra
    Tafuri, Giovanni
    Siviero, Paolo
    GLOBAL POLICY, 2017, 8 : 84 - 92
  • [49] How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
    Shobeiri, Nikta
    Peiravian, Farzad
    Yousefi, Nazila
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2022, 21 (01):
  • [50] MANAGING UNCERTAINTY FOR THE ORPHANS: A BELGIAN PERSPECTIVE ON MANAGED ENTRY AGREEMENTS FOR ORPHAN DRUGS
    Blonda, A.
    Denier, Y.
    Huys, I
    Simoens, S.
    VALUE IN HEALTH, 2022, 25 (12) : S255 - S255
12345